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ABSTRACT
SphK1 is known to play a role in tumor progression, resistance to 
radiochemotherapy, and migration patterns. As the overall survival rates of squamous 
cell carcinoma of the head and neck (HNSCC) remain poor due to limitations in 
surgery and irradiation and chemotherapy resistance, SphK1 is an important 
enzyme to investigate. The purpose of this study was to elucidate the impact of 
SphK1 on irradiation efficacy of HNSCC in-vitro with emphasis on EGFR signaling. 
By immunhistochemical staining we found a positive correlation between EGFR 
and SphK1 expression in patient specimens. In colony formation assays irradiation 
sensitive cell lines showed a poor response to cetuximab, an EGFR inhibitor, and 
SKI-II, a SphK1 inhibitor, and vice versa. In irradiation sensitive cells an enhanced 
reduction of cell migration and survival was found upon simultaneous targeting of 
EGFR and SphK1. In the present study, we elucidated a linkage between the two 
signaling pathways with regard to the efficacy of cetuximab treatment and the impact 
on the migration behavior of tumor cells. We investigated the biological impact of 
inhibiting these pathways and examined the biochemical implications after different 
treatments. An understanding of the processes involved could help to improve the 
treatment of patients with HNSCC.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer worldwide [1]. Mortality 
due to this cancer remains largely unimproved despite 
ongoing advancements in tumor surgery and radio- and 
chemotherapy, with 5-year survival rates under 50% [2]. 
Prognoses of HNSCC disease are often difficult due to 
a poor control of loco-regional disease and significant 
morbidity [3].
An elevated expression of epidermal growth 
factor receptor (EGFR) is significantly associated with 
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a reduced progression-free survival [4]. Indeed, EGFR 
overexpression and alteration has been attributed to 
HNSCC pathogenesis and progression. Hence, anti-
EGFR treatment regimens for HNSCC have been 
implemented [5]. Mechanistically, EGFR targeting 
with the human-murine chimeric immunoglobulin G1 
cetuximab competitively prevents receptor activation by 
endogenous ligands and results in EGFR downreguation 
by internalization of the receptor/antibody complex [6]. 
We previously described an irradiation induced migration 
of HNSCC cell lines that could be linked to EGFR 
overexpression and could be reversed by blocking 
the EGFR activity with the EGFR kinase inhibitor 
AG1478 [7, 8].
Another prognostic indicator for HNSCC is 
sphingosine kinase 1 (SphK1), a lipid kinase that 
catalyzes the conversion of sphingosine to sphingosine-
1-phosphate (S1P), a biologically active lipid that plays 
an important role in mammalian cell growth, survival, 
and migration [9]. It has been shown that SphK1 mRNA 
expression is significantly elevated in several malignant 
diseases e.g., of the breast, colon, uterus, lung, ovary, 
kidney, and rectum [10]. Increased levels of S1P result 
from elevated SphK1 expression/activity and were 
associated with suppression of apoptosis [11], enhanced 
cell growth and migration [12], augmented angiogenesis 
[13], pronounced resistance to irradiation [14], and 
chemotherapy [15, 16]. Similarly, Sinah et al. found a 
correlation between the tumor stage and elevated SphK1 
expression in HNSCC [17].
Receptor crosstalk between members of different 
receptor families is typical for transversal signal 
transduction over the cell membrane [10]. The activation 
mechanisms of SphK1 often involves a variety of growth 
factors, amongst them e.g., platelet-derived growth factor 
(PDGF), EGF, nerve growth factor (NGF), insulin growth 
factor (IGF), and transforming growth factor beta (TGFβ) 
[10]. Naturally, SphK1/S1P tyrosin kinase receptor/
RTK (EGFR) receptor interaction results in a shared 
intracellular signaling network. Hobson et al. found that 
cell migration stimulated by PDGF, which stimulates 
sphingosine kinase and increases intracellular S1P, was 
dependent on the expression of S1P-1-receptor [18]. Shida 
et al. demonstrated that S1P induces the rapid and transient 
tyrosine phosphorylation of EGFR in gastric cancer 
cells [19]. However, studies on intermolecular receptor 
crosstalk in HNSCC are lacking and no information is 
available regarding the impact of anti-EGFR / SKI-II 
targeting, and concurrent irradiation.
In this study we inhibited the SphK1 using 
the non-competitive, kinase specific inhibitor 
2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole (SKI-
II) that does not affect PKCα-, Erk2-, or PI3K-activity 
[20]. SKI-II also has the effect of reducing SphK1 protein 
expression [21]. This inhibitor reduces tumor growth in 
mice and shows a favorable in-vivo half-life period of 15.3 
h [22]. We analyzed EGFR signaling, cell survival, and 
migration as a function of SphK1 targeting in HNSCC cell 
lines.
RESULTS
SphK1 is overexpressed in HNSCC compared to 
normal tissue
Immunhistochemical stainings was done on tumor 
samples of 180 patients. Table 1 shows the clinical data 
of these patients. Immunohistochemistry revealed that 
both proteins, EGFR (p < 0.001) and SphK1 (p < 0.01), 
Table 1: Clinical characteristics of patients included in the study.
Patient characteristics Data
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were significantly higher expressed in the tumor samples 
compared to the non-cancerous tissue (Suppl. Fig. 1).
SphK1 and EGFR expression does not correlate 
with the clinical parameters staging, nodal status, 
metastasis, grading relapse and late metastasis rate. 
Only the lymph node stage and SphK1 overexpression 
were significantly correlated (p = 0.024) (Tab. 2). 
Tumors without a positive lymph node involvement 
more frequently overexpressed SphK1 than those 
with lymph node metastases. In addition, there was a 
highly significant correlation between SphK1 and EGFR 
expression (p = 0.01).
HNCCC cell lines show different sensitivity to 
irradiation
The colony formation assay (CFA) revealed a 
strong impact of irradiation on Cal27 and HN cells, with 
almost 50% of the clones not surviving treatment doses 
of 8 Gy (Cal27, p = 0.0004; HN, p < 0.0001). In contrast, 
the UD-SCC-4 and UD-SCC-5 cells behaved largely 
insensitive to irradiation: The clonogenic survival of 
UD-SCC-4 was not significantly reduced by 5 or 8 Gy 
treatment doses. UD-SCC-5 survival was significantly 
reduced only upon irradiation with 8 Gy (p = 0.0014) 
(Fig. 1) (Suppl. Fig. 2).
Radiation-resistant cell lines are sensitive to SKI-
II and cetuximab therapy
Although the clonogenic survival of UD-SCC-4 and 
UD-SCC-5 cells was not severely affected by irradiation 
the outgrowth of these cell lines was significantly 
inhibited upon treatment with SKI-II and cetuximab 
in a dose-related manner (Fig. 2). Conversely, the 
clonogenic formation of the irradiation sensitive Cal27 
and HN cells was not impaired upon treatment with SKI-
II. The simultaneous administration of both SKI-II and 
cetuximab significantly reduced the clonogenic survival 
of UD-SCC-4, UD-SCC-5 and HN but not Cal27 cells 
(Fig. 2).
Irradiation-sensitive cells show radiation-
induced migration
Irradiation caused a dose dependent increase of 
migration activity in Cal27 whereas UD-SCC-5 cell 
migration was not affected by irradiation treatment. 
HN and UD-SCC-4 cell migration was stimulated by 
irradiation with 5 Gy. Irradiation with 8 Gy did not further 
enhance this effect (Fig. 3 A).
SKI-II inhibits radiation-induced migration
The irradiation-induced migration of Cal27 cells 
was reduced by the simultaneous cell treatment with 0.5 
μM SKI-II (p = 0.0168) but only a trend was seen after 
treatment with cetuximab (0.07 μM). Moreover, the 
combination of both inhibitors did not lead to a further 
inhibition than that of the SKI-II single treatment. 
Accordingly, in HN, UD-SCC-4, and UD-SCC-5 cells 
the combination treatment was most efficient (Fig. 3 B).
Table 2: p-values using Pearson’s Chi-square Test. Cut-off score for samples considered having positive overexpression was 2.
Marker T N G Relapse Metastases
EGFR 0.220 0.195 0.069 0.886 0.365
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E-cadherin expression is inversely correlated 
with irradiation-induced migration activity
Immunofluorescence revealed reduced E-cadherin 
expression in Cal27 cells upon irradiation. E-cadherin 
expression in UD-SCC-5 cells was, however, unaltered 
upon pretreatment with SKI-II (Fig. 4).
SphK1 is upregulation in cetuximab treated UD-
SCC-5 cells
Due to the analogue response rates of Cal27 and HN 
cells on the one hand and the UD-SCC-4 and UD-SCC-5 
cells on the other hand, migration assays were narrowed 
down to Cal27 and UD-SCC-5.
EGFR targeting with cetuximab caused an increased 
receptor phosphorylation both in Cal27 and UD-SCC-5 
cells. Nevertheless, the cetuximab treatment resulted in 
a reduced Akt and Erk1/2 phosphorylation. Strikingly, 
the SphK1 protein expression was upregulated upon 
cetuximab treatment in UD-SCC-5 but not in Cal27 cells 
(Fig. 5).
SKI-II treatment did not alter the SphK1 expression 
and did apparently not affect the Akt activity Cal27 
and UD-SCC-5 cells. In contrast the SKI-II mediated 
inhibition of SphK1 considerably attenuated Erk1/2 
phosphorylation at Thr202/Tyr204 residues.
The combined administration of SKI-II and 
cetuximab caused effects that were analogue to single 
cetuximab treatment although an upregulation of the 
Figure 1: Colony formation assay performed on Cal27, HN, UD-SCC-4, and UD-SCC-5 cell lines as indicated: The cell lines showed 
different response to irradiation. Cal27 und HN cells appeared sensitive to irradiation whereas UD-SCC-4 and UD-SCC-5 cells were not. 
Irradiation-resistant UD-SCC-4 and UD-SCC-5 cell lines showed reduced clonogenic survival upon SKI-II and cetuximab treatment. 
In contrast, the clonogenic survival of irradiation sensitive Cal27 and HN cells is basically not reduced by SphK-1 and EGFR targeting 
with SKI-II and cetuximab.
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SphK1 protein in UD-SCC-5 cells could not be found 
under this treatment conditions.
DISCUSSION
We aimed to elucidate the role of SphK1 in 
HNSCC and the potential interactions with the EGFR 
signaling pathway. The protein expression of SphK1 
and EGFR in the tumor tissues from 180 patients 
was analyzed and compared to the expression in 
non-cancerous tissues. Four human tumor cell lines were 
analyzed for their proliferation and survival capacity 
upon anti-SphK1 targeting with the highly specific SKI-
II inhibitor and anti-EGFR targeting with cetuximab. In 
addition the treatment dependent migration proficiency 
was further analyzed. We used the SKI-II inhibitor 
although it is classified as carcinogenic / teratogenic. 
Blagosklonny, for example, outlined by a number 
of essays, that the carcinogenic/teratogenic effect of 
the substrate is expected from any useful anti-cancer 
drug [23–26].
Figure 2: Colony formation assay performed on the four cell lines: Only combination treatment with SKI-II and cetuximab caused 
reduced clonogenic survival in all four cell lines.
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According to other data [27–29] we found an 
elevated SphK1 and EGFR expression in HNSCC tissues 
compared to non-neoplastic tissues. In addition, we 
report for the first time a significant positive correlation 
of SphK1 and EGFR expression. This finding suggests a 
functional link of SphK1 and EGFR.
CFAs of irradiated and SKI-II / cetuximab treated 
cells revealed two groups of HNSCC cell lines: On the 
one hand UD-SCC-4 and UD-SCC-5 cells manifested as 
irradiation resistant but cetuximab and SKI-II sensitive. 
Treatment with the SphK-1 inhibitor SKI-II even restored 
irradiation sensitivity in these cells (data not shown), 
which has formerly been described elsewhere [17]. On 
the other hand HN and Cal27 cells were sensitive to 
irradiation but were resistant to SKI-II and cetuximab 
treatment. These findings suggest that it might be possible 
to stratify HNSCC patients into potential responders to 
either irradiation or target specific anti-SphK-1/EGFR 
treatment (Fig. 2, Suppl. Fig. 2).
The combination treatment with cetuximab and 
SKI-II exceptionally reduced clonogenic survival of the 
inhibitor-sensitive UD-SCC-4 and UD-SCC-5 cells. The 
inhibition was even more pronounced at reduced doses 
compared to the effects caused by single treatments at 
higher doses (data not shown). The fact that cetuximab 
treatment caused an upregulation of SphK1 expression 
in UD-SCC-5 cells strongly indicates a functional link 
between EGFR and SphK1: It is known that S1P can 
transactivate several RTKs, including EGFR [10] and 
that the transactivation of EGFR involves S1P-3, Src, 
and MMP [19]. It is also known that EGFR downstream 
signaling leads to the activation of Erk1/2 [30] and 
that Erk1/2 activates SphK1 [31] (Fig. 6, illustration in 
black/gray). Furthermore, the downstream signaling of 
S1P receptors 1 and 3 causes activation of Erk1/2 [32] 
and consequently results in an activation of SphK1 [31] 
(Fig. 6, illustration in green). SphK1 is located at the 
critical point of a complex amplification loop, and this 
Figure 3: Wound healing assay: The radiation-sensitive cell line Cal27 reacted with a dose-dependent increase in migration after 
irradiation; in contrast, the resistant cell line UD-SCC-5 exhibited no radiation-induced migration. The HN and UD-SCC-4 cell lines 
shows a slightly increase of migration. The application of SKI-II and the combined administration of SKI-II and cetuximab inhibited Cal27 
cell radiation-induced migration. The combination of inhibitors did not lead to an advantage compared to the single SKI-II treatment. 
Conversely, the single treatment of the inhibitors showed little impact on UD-SCC-5 cell migration patterns. Their combination, however, 
led to a significant reduction in migration, hence showing a significant advantage compared to the single treatment according to the CFA 
results.
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Figure 4: Immunofluorescence staining: Radiation doses of 8 Gy led to the degradation of E-cadherin in Cal27 cells; this effect, however, 
was obviated after pretreatment with SKI-II. Irradiation did not affect E-cadherin in UD-SCC-5 cells. SKI-II improved cell adhesion by 
upregulating the E-cadherin protein.
Figure 5: Western blot analyses: Cetuximab caused an increase in EGFR phosphorylation, which was not transmitted to the downstream 
Erk1/2 and Akt signaling pathways. Cetuximab also caused an upregulation of SphK1 protein in UD-SCC-5 cells but not in Cal27 cells. 
In UD-SCC-5 cells, however, the effect was attenuated by the addition of SKI-II.
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loop can apparently be broken through the combined 
treatment of cetuximab and SKI-II (Fig. 6).
Cell migration is essential for metastasis. 
Previous studies revealed a connection between SphK1 
overexpression and migration capacity [12]. Here we 
show that SphK-1 and EGFR targeting with SKI-II and 
cetuximab inhibits the migration ability of HNSCC cell 
lines. Consistent with the reduced capacity to form cell 
colonies, we found an additive effect in UD-SCC-5 but 
not in Cal27 cells when both inhibitors were applied at the 
same time. Again a functional link between the SphK1 and 
EGFR signaling must be assumed.
Irradiation is an established treatment strategy 
for HNSCC patients. We previously reported radiation-
induced migration in HNSCC cell lines [8]. The 
underlying mechanisms are, however, barely understood. 
Here we demonstrate that radiation-induced migration 
is more pronounced in cell lines that are sensitive to 
irradiation than in resistant cell lines. The irradiation 
enhanced migration capacity observed in Cal27 cells goes 
along with a downregulation of E-cadherin. Accordingly, 
the inhibition of SphK-1 by SKI-II treatment results in an 
upregulation of E-cadherin and simultaneously reduces 
the radiation-induced migration of Cal27 cells. The 
combination treatment with both inhibitors significantly 
affects the wound healing of UD-SCC-5 but not of Cal27. 
Thus, SphK1 and EGFR most likely affect the radiation-
induced migration independently.
Cetuximab treatment of Cal27 and UD-SCC-5 cells 
caused EGFR phosphorylation at Tyr1068 but reduces 
the phosphorylation of Erk1/2 and Akt (Fig. 5). This 
finding is in agreement with data published elsewhere 
[33]. Even more strikingly, UD-SCC-5 cell treatment with 
cetuximab caused an upregulation of SphK1 protein that 
might abrogate the desired anti-tumorigenic effect. The 
SphK1 upregulation can, however, be repressed by the 
combined anti-EGFR / anti-SphK1 targeting that restores 
the sensitivity to either drug treatment.
In contrast to data published elsewhere [20] 
we found a decreased p-Erk1/2 Thr202/Tyr204 
phosphorylation upon SKI-II treatment. This discrepancy 
can be explained by a reduced SphK1 product S1P upon 
treatment with SKI-II, because S1P can activate the S1P 
receptor and the downstream Erk1/2 signaling [32]. 
Moreover, S1P can transactivate RTKs (e.g. EGFR) and 
thus can cause Erk1/2 activation [10].
Overall, we provide strong evidence for a functional 
SphK1/EGFR interaction. To explain the effects described 
above, we developed the model illustrated in Fig. 6: 
Receptor specific targeting affects downstream signaling 
Figure 6: Model of EGFR/SphK1 interaction: SphK1 is a component of different amplification loops. One loop involves the transactivation 
of EGFR by S1P, causing the activation of Erk1/2 and thus the activation of SphK1. The other loop involves the activation of S1P receptors 
1 and 3. Downstream signaling causes the activation of Erk1/2 via Ras and Erk1/2 is known to activate SphK1. Integrating these two 
amplification loops into one model leads to a new understanding of EGFR- and SphK1-targeted therapies, as treatment targeting EGFR 
only inhibits one loop. By western blot analyses, we found a compensatory upregulation of SphK1 after cetuximab treatment, leading to 
attenuated effects of the drug, as observed by CFA and WHA. However, blocking both loops and thus inhibiting the upregulation of the 
SphK1 protein leads to improved results of target therapies.
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pathways of either receptor system and consequently 
tumor cell survival and migration. We suggest that 
cetuximab treatment, blocks just one of the associated 
signaling loops that results in a compensatory upregulation 
of the SphK1 protein (Fig. 6, green illustration). This in 
turn promotes the other signaling loop. Consequently, 
HNSCC treatment can be most efficiently improved by 
a synchronous targeting of both signaling loops i.e., by 
a combined anti SphK1/anti-EGFR treatment (Fig. 6, 
effecting green and black/gray loop). Our results indicate 
that the amplification loop is active in tumors that are 
sensitive to the inhibitors (e.g., represented by UD-
SCC-5 cells) though resistance to inhibitors cannot be 
overcome by a combined treatment. Our results suggest 
the side effects of cetuximab treatment could possibly be 
ameliorated by a dose reduction.
CONCLUSION
HNSCC cell lines (investigated in this study) can 
be graduated in 2 groups: the first is irradiation resistant 
but cetuximab and SKI-II sensitive, the second react 
conversely.
SKI-II was found to reduce malignancy in all cell 
lines, either directly by inhibiting proliferation, survival, 
and migration, or indirectly by inhibiting irradiation-
induced migration. Also, a combination treatment with 
SKI-II and cetuximab could work efficiently in tumor 
cells which basically respond well to cetuximab treatment 
alone, because then lower cetuximab doses were required. 
However, possible side effects of SKI-II especially in 
combination treatments need to be further explored. The 
high effects achieved with the combination of cetuximab 
and SKI-II can most likely be attributed to positive 
signaling amplification loops between the EGFR- and 
SphK1 related pathways, although resistance to cetuximab 
or SKI-II could not be overcome by their combination. 
Therefore, we conclude that these amplification loops 
do not play a role in the development of resistance to 
cetuximab or SKI-II.
Currently, the therapy of patients with HNSCC in 
the advanced stage III and IV implies primary radiotherapy 
in combination with chemotherapy [34]. Our data indicate 
that a change in the therapeutic strategies of patients with 
HNSCC might be useful. Inhibition of the EGFR and 
SphK1 in combination with the radiotherapy might be an 




Formalin-fixed and paraffin-embedded tumor 
samples from 180 patients with a squamous cell carcinoma 
of the oral cavity (n=33), oropharynx (n=58), hypopharynx 
(n=33), or larynx (n=56) were examined for EGFR and 
SphK1 expression. The expression levels were compared 
to non-cancerous tissue from the same patient.
The Medical Ethics Committee of the Technical 
University of Munich approved this study.
Tissue microarray preparation
Core needle biopsies of viable, representative areas 
of each tumor specimen were retrieved from the original 
tumor blocks using a manual array (Beecher Instruments, 
Sun Prairie, Wisconsin, USA) and placed in a recipient 
paraffin array block. The goal was to obtain at least three 
tissue cylinders, with a diameter of 0.6 mm, from each 
biopsy specimen.
Immunohistochemical staining
Fresh 1.5 μm sections from TMA blocks were 
transferred to glass slides, deparaffinized, and rehydrated. 
An antigen retrieval method (microwave oven heating 
in citrate-buffered saline) was applied following the 
instructions provided by the manufacturer. The TMA slides 
were cooled and incubated with antibodies against EGFR 
(rabbit, clone D38B1) 1:200 (Cell Signaling Technology, 
Danvers, USA) and SPHK1 (rabbit) 1:200 (Cell Signaling 
Technology, Danvers, USA). The reaction was developed 
using the labeled streptavidin-biotin-peroxidase system; 
DAB was used as the indicator. After counterstaining with 
hematoxylin, the slides were dehydrated in ascending 
concentrations of ethanol and mounted. Tissue with known 
expression of the respective antigen was used for a positive 
control; irrelevant antibodies of the immunoglobulin 
isotype were used as negative control.
Scoring system for protein expression
A scoring system was used to describe the 
expression levels of the different proteins. The staining 
intensity was graded from 0 to 3 points (0 points = no 
staining, 1 point = low staining intensity, 2 points = 
moderate staining intensity, 3 points = strong staining 
intensity). The proportion of stained cells was estimated 
and graded from 0 to 4 points (0 points = 0% of the tumor 
cells, 1 points = <10% of the tumor cells, 2 points = 10%-
29% of the tumor cells, 3 points = 30%-59% of the tumor 
cells, 4 points = 60%-100% of the tumor cells). Both 
scores were added to produce a cumulative score.
Cell culture
The Cal27 and HN cell lines were obtained from 
DSMZ (Braunschweig, Germany), and UD-SCC-4 and 
UD-SCC-5 cells were obtained from the University 
of Düsseldorf (clinic for otolaryngology, Düsseldorf, 
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Germany) (Tab. 3) [35]. The cells were cultured in 
Dulbecco's modified Eagle medium (DMEM) (Invitrogen, 
Darmstadt, Germany) containing 10% fetal calf serum 
(FBS) (Biochrom, Berlin Germany), 2 mM glutamine 
(Biochrom), 100 μg/ml streptomycin (Biochrom), and 
100 U/ml penicillin (Biochrom), maintained at 37°C in an 
atmosphere of 5% CO2, and grown to 70–90% confluence.
Irradiation
Irradiation was performed at the Department of 
Radiotherapy (Technical University of Munich). The 
cells were X-irradiated with single doses of 5 or 8 Gy at 
room temperature using a Gulmay Medical X-ray source 
operated at 70 kV and a dose rate of approximately 1 Gy/
min. The sham-treated group (0 Gy, control) was subjected 
to the same protocol as the exposed cells.
Inhibitors
SphK1 was specifically inhibited using 
2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI-
II) (Merck, Darmstadt, Germany) at concentrations of 
0.5 μM and 1 μM. Cetuximab was purchased from Merck 
(Darmstadt, Germany) and used at concentrations of 0.07 
μM and 0.14 μM.
Colony formation assay
Cell survival was assessed by a colony formation 
assay (CFA). The cells were seeded in a 6-well plate (5 × 
102 cells/well). After 1 d, the cells were pretreated with 
cetuximab and SKI-II for one hour and subsequently 
irradiated; the cells were then cultured for 10 days. The 
cell colonies were formalin fixed and visualized by Crystal 
Violet staining (Aldrich Chemie, Steinheim, Germany); 
the colonies were counted after removing the dye by 
washing.
Wound-healing assay
Cell migration was assessed by wound-healing 
assays (WHA). Cells were seeded in a 6-well plate (5 x 
105 cells/well), and a scratch was drawn into the cell layer 
after 2 d of incubation. The cells were then pretreated with 
inhibitors and optionally irradiated. Pictures of the scratch 
were obtained directly after and at 12 h after the treatment. 
The number of pixels covering with cells was evaluated 
using Photoshop, and the magnitude of the points of 
measurement was compared using the following formula:
((T2-T1) / 5038848) x 100
(T1 = 5038848 – the number of pixels at the start of 
measurement)
(T2 = 5038848 – the number of pixels after 12 h)
(5038848 = the total number of pixels)
Immunofluorescence
For immunofluorescence (IF), slides were coated 
with 0.1% gelatin, and 2.5 x 105 cells/slide were seeded. 
After 2 d of incubation, the cells were pretreated with 
inhibitors and irradiated. At 1 h after treatment, the 
cells were formalin fixed and stained with antibodies 
against the following proteins: E-cadherin (mouse) 
(Enzo Life Science, Lörrach, Germany), 1:200; EGFR 
(rabbit) (Santa Cruz Biotechnology, Dallas, Texas), 
1:200; and SphK1 (rabbit) (Cell Signaling Technology, 
Danvers, USA), 1:200. Anti-rabbit-FITC (Cell Signaling 
Technology, Danvers, USA) and anti-mouse-Cyp3 
(Cell Signaling Technology, Danvers, USA) were used 
for detection at a dilution of 1:200. The nuclei were 
stained with DAPI (1 μg/ml) before mounting cells 
with VectaShield® (Vector Laboratories, Burlingame, 
USA). Fluorescence images were captured with a Leica 
epifluorescence confocal microscope equipped with a 
digital camera and Leica Application Suite LAS V3.7 
acquisition software.
Western blotting
For protein isolation, the cells were starved under 
serum-free conditions for 12 h. One hour after treatment, 
the cells were lysed in 1x lysis buffer (New England 
Biolabs, Ipswich, USA) supplemented with 1 mM PMSF 
(Roth, Karlsruhe, Germany). Equal amounts of protein 
(15 μg) were separated by SDS-PAGE and transferred to 
Table 3: Data (HPV and p53 status raised in our lab) and clinical characterization of the cell lines used in the study.
Cell line Localisation TNM Grading Age Sex HPV p53
Cal 27 oral cavity Tx Nx Mx G3 56 male negativ Exon6 c.578a>t (H193L)
HN oral cavity Tx Nx M1 G2 60 male negativ Exon6 c.578a>t (H193L)
UD-SCC-4 oropharynx T3 N1 M0 G2 45 male negativ Exon5 c.454c>g, c.557c>t, del. 460–472
UD-SCC-5 larynx T1 N1 M0 G3 44 male negativ Exon5 c.535c>t (H179Y)
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Immobilon membranes (Millipore, Schwalbach, Germany). 
The blocking of nonspecific binding sites was performed 
using 5% (w/v) non-fat dry milk in TBST. The membranes 
were incubated with primary antibodies diluted in TBST 
for 12–14 hours at 4°C. HRP-conjugated immunoglobulins 
(diluted 1:5000 in 5% non-fat dry milk/TBST) served as 
detection antibodies and were probed for 1 h at room 
temperature. The immunoreactivity was visualized by 
exposure to high-performance chemoluminescence film 
(Biorad Laboratories, Munich, Germany). Antibodies 
against the following were used: p-EGFR Tyr1068 
(Rabbit) (New England Biolabs) (1:2500); EGFR (Rabbit) 
(Santa Cruz Biotechnology, Dallas, Texas) (1:2500); 
p-Akt Ser473 (Rabbit) (New England Biolabs) (1:500); 
Akt (Rabbit) (New England Biolabs) (1:1000); p-Erk1/2 
Thr202/Tyr204 (Rabbit) (New England Biolabs) (1:1000); 
Erk1/2 (Rabbit) (New England Biolabs) (1:1000); SphK1 
(Rabbit) (New England Biolabs) (1:500); tubulin (Mouse) 
(Sigma Aldrich Chemie, Steinheim, Germany) (1:10000); 
anti-Rabbit HRP-linked IgG (Goat) (New England 
Biolabs) (1:5000); and anti-Mouse HRP linked IgG (Goat) 
(New England Biolabs) (1:2000).
Statistical analysis
A statistical analysis of the protein expression in 
the tumor samples was performed using SPSS Statistics 
software (version 18/19, IBM, Munich, Germany). The 
relationship between the two proteins was tested by 
crosstabs and the Fisher exact test. Results with p-values 
<0.05 were considered significant. A statistical analysis 
for the in vitro experiments was performed using Prism 
Graph Pad 5.0 software. Assuming a symmetry correlation 
structure for all the experiments, all the hypotheses 
were tested with a one-way ANOVA. We compared the 
separate treatments and the untreated control for statistical 
significance with a t-test (p-values < 0.05).
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